Aims: To determine the specific role of podocyte-expressed cannabinoid-1 receptor (CB 1 R) in the development of diabetic nephropathy (DN), relative to CB 1 R in other renal cell types.
processes form slits that represent 1 layer of the glomerular filtration barrier and enable the efficient ultrafiltration of blood to form tubular fluid. 3 The structural integrity of podocytes is key for proper glomerular function, and podocyte injury underlies the progression of several renal pathologies. 4 Additionally, podocytes interact with mesangial and glomerular endothelial cells through various paracrine mediators to maintain normal glomerular functions, and disruption in this cellular cross-talk may contribute to DN. 5, 6 The endocannabinoid system (ECS) is comprised mainly of 2 membrane receptors (CB 1 R and CB 2 R) and their 2 major endogenous ligands, N-arachidonoyl-ethanolamine (anandamide or AEA) and 2-arachidonoyl-glycerol (2-AG). In addition to its well-documented role in obesity and its metabolic complications, 7 the ECS has been implicated in the pathogenesis of CKD, including DN. 8, 9 Both CB 1 R and CB 2 R are expressed in the human and rodent kidney, 8 particularly in mesangial cells, 10 podocytes 11 and proximal tubular cells. 12, 13 Enzymes responsible for the biosynthesis and degradation of endocannabinoids are also expressed in the kidney. 9, 14 We have previously reported that CB 1 R activation in podocytes mediates podocyte injury caused by hyperglycaemia and increased RAAS activity in a rat model of T2D. 11 Furthermore, in vitro exposure of podocytes to high glucose increases CB 1 R expression, and this effect is abrogated by CB 1 R blockade. 15 However, the specific role of CB 1 R in podocytes in the development of DN, relative to CB 1 R in other renal cell types, remains unclear. Here we report that podocyte-specific genetic deletion of CB 1 R partially protects against the streptozotocin-induced glomerular dysfunction and, surprisingly, also prevents proximal tubular injury, possibly by improving the renal microcirculation and, also, by preventing the release of humoral factors involved in tubular damage from podocytes. These observations highlight the key pathogenic role of podocyte CB 1 R in DN.
2 | RESULTS
| High-glucose activates the ECS in podocytes and promotes podocyte injury
Chronic exposure of human cultured podocytes to high-glucose (30 mM) elicited a significant increase in CNR1, but not CNR2 expression, within 48 hours, as compared to cells exposed to 5 mM glucose.
This was accompanied by an increase in the cellular levels of AEA and interleukin-18 (IL-18) ( Figure 1C ). Furthermore, gene expression of transforming growth factor β1 (TGFB1) was similarly strongly increased ( Figure 1D ). To determine whether these changes were related to CB 1 R activation, we exposed podocytes to 30 mM highglucose for 48 hours in the presence of CNR1-siRNA. Treatment with CNR1-siRNA completely abolished the high-glucose-induced CNR1 overexpression, reducing CNR1 mRNA significantly below that of cells maintained in normal glucose, without influencing CNR2 expression ( Figure 1E ). In addition, CNR1 knock-down completely prevented the high-glucose-induced podocyte injury, as indicated by the normalization of podocin (NPHS2), nephrin (NPHS1) and desmin (DES) gene expression ( Figure 1F ). The high-glucose-mediated secretion of CCL2, TNF-α, IL-18 and TGFB1 expression were also significantly attenuated by CNR1 knockdown ( Figure 1E , G). To establish whether these observations were relevant in vivo, we developed a mouse model with a podocyte-specific deletion of Cnr1.
2.2 | Podocyte-specific deletion of Cnr1 mitigates the loss of glomerular function in streptozotocintreated diabetic mice
Deletion of Cnr1 in podocytes was first assessed by cell-specific genotyping. Podocytes-nuclei stained for the marker Wilms' tumor-1 (WT-1) were laser captured using the xMD method. Compared to wild-type podocytes, pCB1Rko podocytes showed a shift in the DNA band for Cnr1 in WT-1 + but not WT-1 − nuclei ( Figure S1A ), indicating podocyte-specific deletion of Cnr1. The absence of CB 1 R protein in podocytes was confirmed by co-localization with podocalyxin as visualized by double immuno-fluorescence/confocal microscopy ( Figure S1B ). The phenotype of pCB1Rko mice was indistinguishable from that of their wild-type Cre + littermates, displaying comparable body and kidney weights and normal parameters of kidney function.
They also had similar endocannabinoids levels, but half as much CB 1 R mRNA in the renal cortex as compared to wild-type littermates ( Figure 2 ). At 12 weeks after STZ-treatment to induce hyperglycaemia, body weight of the 2 strains remained similar, but wild-type mice had higher kidney weight ( Figure 2A ) and higher Cnr1 expression in renal cortices as compared to diabetic pCB1Rko mice ( Figure 2B ).
Meanwhile, cortical levels of AEA and 2-AG remained similar in the 2 strains ( Figure 2C ).
Wild-type and pCB1Rko mice developed similar STZ-induced hyperglycaemia and a similar increase in hA1c ( Figure 2D ). However, after 12 weeks of chronic hyperglycaemia, pCB1Rko mice displayed significantly lower levels of blood urea nitrogen (BUN) and less albuminuria compared to their STZ-treated wild-type littermates ( Figure 2E ), suggesting better preserved glomerular and podocyte functions in the former. Correspondingly, pCB1Rko mice were protected from podocyte loss, as demonstrated by significant preservation of WT-1 and podocalyxin immunostaining ( Figure 2F ). In addition, diabetic wild-type mice displayed an increase in glomerular tuft area, which remained normal in diabetic pCB1Rko mice ( Figure 2F ). These histological observations were consistent with altered gene expression profiles. Indeed, the diabetes-induced decrease in the expression of genes encoding for structural podocyte proteins such as Nphs2, Nphs1 and zonula occludens (Tjp1) was absent in diabetic pCB1Rko mice ( Figure 2G ). Interestingly, the diabetes-induced increased expression of Des, which correlates with podocyte injury, was not influenced by the deletion of CB 1 R in podocytes ( Figure 2G ). Structural analysis by electron microscopy revealed mild segmental/variable thickening of glomerular basement membranes (GBM) with foot process fusion in the STZ-treated wildtype mice and focally shorter foot processes. In contrast, podocyte foot processes and GBMs were comparable between the citrate-and STZ-treated pCB1Rko mice, although minor irregularities could be appreciated in the GBM thickness of STZ-treated pCB1Rko mice ( Figure S2 ).
| Podocyte-specific deletion of Cnr1 partially prevents proximal tubular cell injury and loss of function
In addition to its protective effect on podocyte function, podocytespecific deletion of Cnr1 also protected some tubular cell functions.
For instance, pCB1Rko mice had lower urine output, less glycosuria and urinary N-acetylglucosamine (NAG) activity, and increased expression of the proximal tubular cell marker megalin (Lrp2) in renal cortices as compared to their wild-type littermates ( Figure 3A ). Interestingly, diabetic wild-type and pCB1Rko mice displayed similar increases in expression of the sodium/glucose cotransporter 2 -(SGLT2, Slc5a2) protein despite different levels of glycosuria ( Figure 3A) . Again, no differences in gene expression were observed under non-diabetic conditions, with the exception of a small increase in Lrp2 expression in pCB1Rko as compared to wild-type mice.
Alterations in arginine metabolism, as reflected by increased expression of Arg2, results in vascular dysfunction in diabetes, which contributes to the pathogenesis of DN. 16 We observed a strong increase in arginase-2 protein in renal cortices from diabetic mice compared to non-diabetic wild-type mice, whereas no such increase was detectable in diabetic pCB1Rko mice ( Figure 3B ). Furthermore, lipocalin 2 has been linked to tubular cells apoptosis and renal lesion, 17 and its protein and gene expression was strongly increased by diabetes in wild-type mice, and much less so in pCB1Rko mice ( Figure 3B ). Renal cortical fibrosis was evident in diabetic wild-type, but not in pCB1Rko mice, as documented histologically by PicroSirius Red staining and by corresponding changes in the gene expression of pro-fibrotic markers Col1a, Timp1, Tgfb1 and Fn1 ( Figure 3B ).
Furthermore, the commonly observed hyperglycaemia-induced increase in caspase 3/7 activity was also attenuated in diabetic pCB1Rko as compared to diabetic wild-type mice ( Figure 3C ).
| Absence of CB 1 R in podocytes prevents the diabetes-induced increase in oxidative stress and inflammation in renal cortices
In wild-type mice, diabetes was associated with increased ROS production in renal cortices and corresponding increases in the . E, BUN and albuminuria in citrate buffer-treated wild-type (blue columns, n = 10) or pCB1Rko mice (red columns, n = 10) and streptozotocin-treated wild-type (blue hatched columns, n = 12) or pCB1Rko mice (red hatched columns, n = 15). F, Podocyte numbers assessed by immunohistochemistry using Wilms' Tumor 1 (WT-1) or podocalyxin staining to evaluate the number of nuclei and podocyte membrane integrity (scale bars, 50 μm). Glomerular tuft area quantification after PAS staining. G, Gene expression for podocin (Nphs2), nephrin (Nphs1), Zonula occludens (Tjp1) and desmin (Des) in citrate buffer-treated wild-type (blue columns, n = 10) or pCB1Rko mice (red columns, n = 10), and streptozotocin-treated wild-type (blue hatched columns, n = 12) or pCB1Rko mice (red hatched columns, n = 15). Columns and bars represent means AE SEM. Significant differences from values in citrate buffer-treated wild-type mice (*P < .05, **P < .01, ***P < .001) or streptozotocintreated wild-type mice (#P < .05, ##P < .01, ###P < .001) expression of ROS-generating NADPH oxidase isoforms, such as NADPH oxidase4 (Nox4), p47phox and Nox1. On the other hand, no such diabetes-induced changes were detected in pCB1Rko mice ( Figure 4C ).
| Absence of CB 1 R in podocytes mitigates diabetes-induced hypoxia and decrease in renal microcirculation
Microvascular density has been suggested as a component of CKD progression and, as such, may be impacted in diabetes, 18, 19 resulting in chronic hypoxia. 20 Because the genetic deletion of CB 1 R in podocytes had a protective effect on both glomerular and tubular functions, we explored the possibility of a parallel improvement in renal microcirculation, as assessed by Laser speckle contrast analysis (LASCA), 21, 22 where changes in cortical blood flow are evident during renal ischemia/reperfusion ( Figure S3 ). Under normal conditions, wild-type and pCB1Rko
mice had similar levels of renal microcirculatory flux. However, diabetes (Lrp2) and sodium-glucose co-transporter 2 (SGLT2 Slc5a2). B, Arginase-2 and lipocalin-2 protein expression analysis by immuno-staining (scale bars 100 μm) and fibrosis assessment by Picro-Sirius red staining (scale bars 100 μm) and cortical gene expression of collagen 1 (Col1a), metallopeptidase inhibitor 1 (Timp1), TGF-β (Tgfb1) and fibronectin (Fn-1). C, Caspase 3/7 activity in renal cortices from citrate buffer-treated wild-type (blue columns, n = 10) or pCB1Rko mice (red columns, n = 10) and streptozotocin-treated wild-type (blue hatched columns, n = 12) or pCB1Rko mice (red hatched columns, n = 15). Columns and bars represent means AE SEM. Significant differences from values in citrate buffer-treated wild-type mice (*P < .05, **P < .01, ***P < .001) or streptozotocin-treated wild-type mice (#P < .05, ##P < .01, ###P < .001) FIGURE 4 Cnr1 deletion in podocytes reduces oxidative stress, macrophages infiltration and renal inflammation while improving renal microcirculation. A, Reactive oxygen species (ROS) quantification in renal cortices and gene expression of NADPH oxidase 4 (Nox4), NADPH oxidase 1 (Nox1) and neutrophil cytosolic factor 1 (p47phox). B, Macrophage infiltration as assessed by Iba-1 immuno-staining (scale bars: 100 μm) and cortical gene expression of the macrophage markers CD68 (Cd68) and F4/80. C, Gene expression of CCL2 (Ccl2), TNF-α (Tnf), IL-6 (Il6), IL-1β (Il1b) and IL-18 (Il18) in renal cortices from citrate buffer-treated wild-type (blue columns, n = 10) or pCB1Rko mice (red columns, n = 10) and streptozotocin-treated wild-type (blue hatched columns, n = 12) or pCB1Rko mice (red hatched columns, n = 15). D, Representative illustration of renal microcirculation assessment by Laser speckle contrast analysis. E, Immunoreactive HIF-1α and VEGF-A protein expression and mRNA levels in renal cortical sections; thrombospondin-1 (Thbs1) and NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, 4-like 2 (Ndufa4l2) gene expression is also shown. F, Pyruvate, lactate concentration and lactate/pyruvate ratio in renal cortices from citrate buffertreated wild-type (blue columns, n = 10) or pCB1Rko mice (red columns, n = 10) and streptozotocin-treated wild-type (dark hatched columns, n = 12) or pCB1Rko mice (red hatched columns, n = 15). Columns and bars represent means AE SEM. Significant differences from values in citrate buffer-treated wild-type mice (*P < .05, **P < .01, ***P < .001) or streptozotocin-treated wild-type mice (#P < .05, ##P < .01, ###P < .001) in wild-type mice resulted in decreased renal microcirculation, while no such decrease was evident in pCB1Rko mice ( Figure 4D ). Additionally, in renal cortices from diabetic wild-type mice, the gene and protein expression of hypoxia-inducible factor-α (Hif1a) was increased, and that of vascular endothelial growth factor-A (Vegfa) was reduced, relative to control wild-type mice ( Figure 4E ). Furthermore, diabetic renal cortices displayed increased gene expression of the angiogenic factor thrombospondin-1 (Thsb1) and of the HIF-1α target, NADH dehydrogenase-1α subcomplex 4-like2 (Ndufa4l2), 23 as well as an increase in the lactate-to-pyruvate ratio, a marker of tissue hypoxia, relative to non-diabetic controls ( Figure 4F ). These diabetes-related changes were absent or attenuated in diabetic pCB1Rko mice, suggesting that podocyte CB 1 R activity plays a critical role in mediating the decrease in renal cortical blood flow and, thus, the resulting tissue hypoxia.
| Podocyte-derived factors regulate proximal tubular cell function
To further explore the possible involvement of podocyte-derived factors in damaging tubular cell function, we prepared conditioned medium (CM) from podocytes exposed to high glucose for 48 hours. ( Figure 5B) . Interestingly, the minimal effects of high glucose on RPTC's CCL2, TNF, IL18 and TGFB expression were significantly increased by exposure to podocyte-CM, particularly for CCL2 expression, which was dramatically increased ( Figure 5C ). The potentiation of the effects of high glucose by podocyte-CM was fully or partially abrogated in the presence of JD5037 ( Figure 5C ).
For a detailed description of materials and methods, see File S1
and S3. Podocyte-derived factors potentiate high glucose-induced proximal tubular cell injury A, CNR1 gene expression in human RPTC exposed to normal glucose (white), high glucose (black), podocyte-conditioned medium (green) or podocyte-conditioned medium containing 100 nM JD5037 (green with white hatch). B, LRP2, LCN2, VIM-1 and ARG2 gene expression in RPTC exposed to normal glucose (white), high glucose (black), podocyte-conditioned medium (green) or podocyte-conditioned medium with JD5037 (green with white hatch). C, CCL2, TNF, IL18 and TGFB gene expression in RPTC exposed to normal glucose (white), high glucose (black), podocyte-conditioned medium (green) or podocyte-conditioned medium with JD5037 (green with white hatch). D, Schematic illustration of the proposed mechanism by which CB1R-expressed podocytes mitigate podocyte and tubular injury. This illustration was prepared using a template on the Servier medical art website (http://www.servier.com/Powerpoint-image-bank). Columns and bars represent means AE SEM from 2 independent experiments and 6 replicates per group. Significant differences from values in RPTC in normal glucose (*P < .05, **P < .01, ***P < .001. Significance of the effect of JD5037 in RPTC in high glucose #P < .05, ##P < .01, ###P < .001. Significance of the effect of conditioned medium in RPTC in high glucose (&P < .05, &&P < .01, &&&P < .001) induces tubular dysfunction, fibrosis and the reduction of renal cortical microcirculation in STZ-induced DN. Lastly, we demonstrate that soluble factors released by podocytes in response to CB 1 R activation may mediate crosstalk between podocytes and proximal tubular epithelial cells.
| DISCUSSION
An upregulation of renal CB 1 R has been linked to the development of DN 10, 11, 24, 25 and renal fibrosis. 26 In turn, CB 1 R antagonists have been identified as potential therapeutic tools, as the globally active CB 1 R antagonist rimonabant ameliorates albuminuria and reduces glomerular and tubular damage in rodent models of obesity/diabetes, 15, 25 and also reduces albuminuria in STZ-treated mice with type-1 DN. 24 Although the clinical use of rimonabant is precluded by its CNS-mediated side effects, peripherally restricted CB 1 R antagonism is devoid of such undesired effects, while remaining effective in maintaining and restoring podocyte integrity and functions in a rat model of type-2 DN. 11 However, the cellular localization of CB 1 R responsible for these effects is not clear, as gluco-and/or lipotoxic stress increases CB 1 R expression, not only in podocytes, 15 but also in renal cortical mesangial cells 10 and proximal tubular cells, 13, 27, 28 and CB 1 R activation leads to the apoptosis of both cell types. 10, 28 In order to investigate the specific role of podocyte CB 1 R in DN,
we developed the first podocyte-specific CB 1 R knock-out mouse One possible explanation for this unexpected finding is that an improvement in glomerular filtration and a reduction in albuminuria and other filtered tubulotoxins directly leads to decreased proximal tubulointerstitial damage. [29] [30] [31] We have found that the absence of CB 1 R from podocytes mitigated the hyperglycaemia-induced lipocalin 2 overexpression in tubular cells, which may be related also to the decrease in albuminuria in diabetic pCB1Rko mice, as it was previously shown that an increase in albumin promotes tubular cell death by inducing Ca 2+ -dependent endoplasmic reticulum stress, leading to lipocalin 2 overexpression. 17 Similarly, an increase in albumin can induce TNF-α, CCL2 and platelet-derived growth factor secretion by tubular cells, and these cytokines can serve as a trigger for the development of interstitial fibrosis. 32, 33 This deleterious effect of albuminuria can be facilitated by the high glucose-mediated increase in metalloproteinase activity in tubular cells that leads to the shedding of the megalin/cubilin complex, which contributes to the impaired tubular clearance of filtered proteins including albumin, 34, 35 as they are partially reabsorbed via megalin. 36 The tubular expression of megalin is reduced during obesity or diabetes and is restored by pharmacological inhibition of CB 1 R, 11, 37 as demonstrated in the present study.
Another explanation involves a paracrine interaction between podocytes and renal proximal tubular cells (RPTC 26 Similarly, pharmacological blockade of CB 1 R using rimonabant abolished the high glucose-mediated increase in profibrogenic genes in cultured podocytes. 15 These results are in agreement with the profibrogenic role of podocyte CB 1 R and their additional involvement in the associated macrophage infiltration in both glomeruli and the interstitial space around tubular cells, which maintains a pro-inflammatory environment.
Contrary to our findings, Barutta et al. reported that the overexpression of the pro-fibrotic proteins, TGF-β and fibronectin, and the connective tissue growth factor in the cortex, was unaltered by the CB 1 R antagonist rimonabant in STZ-treated mice. 24 However, in a more recent study using the same model, they found significant suppression of pro-fibrogenic gene and protein expression by the peripherally restricted neutral CB 1 R antagonist AM6545. 48 Furthermore, in db/db mice with type-2 DN, CB 1 R blockade with rimonabant decreased albuminuria and suppressed the cortical expression of profibrotic (TGF-β1, type IV collagen, PAI-1) and pro-inflammatory markers (CCL2). 15 Together, these findings support the pro-fibrogenic role of CB 1 R in the kidney.
Primary glomerular disease disrupts blood flow into the interstitium as the result of changes in vascular tone. Such microvascular changes appear prior to the decline in kidney function in STZ-treated rats. 18 Moreover, interstitial fibrosis and extracellular matrix accumulation impair oxygen diffusion to tubular and interstitial cells by increasing the distance between blood vessels and nearby cells, 49 leading to tissue hypoxia. Our observations of diabetic wild-type kidney are compatible with those in advance-stage renal cortical hypoxia, as evidenced by reduced cortical microcirculation, reduced
Vegfa expression, probably resulting from endothelial cell apoptosis, 50 increased Hif1a, thbs1, ndufa4/2 gene expression and increased lactate-to-pyruvate ratio, which are all markers of tissue hypoxia.
Strikingly, the absence of podocyte CB 1 R mitigated all of these diabetes-induced changes, suggesting a critical role of podocyte Figure 5D .
